The latest announcement is out from Skye Bioscience (SKYE).
Skye Bioscience, Inc. expanded its Board from eight to nine members and welcomed Dr. Karen L. Smith, who brings a wealth of expertise with her impressive MD, PhD, MBA, and LLM credentials. Dr. Smith will actively contribute to the company’s governance, compensation, and auditing committees, and as an incentive, she receives a competitive retainer and stock options. Meanwhile, the resignations of Dr. Keith Ward and Dr. Praveen Tyle were announced, effective August 1, 2024, with no disagreements cited as the reason for their departure. The company publicly shared the news of Dr. Smith’s appointment, underscoring the strategic efforts to strengthen its leadership team.
Learn more about SKYE stock on TipRanks’ Stock Analysis page.
